Print Edition – Article Beyond the Pharmaceutical Patent Arms Race Maya M. Durvasula & Lisa Larrimore OuelletteVolume 43 • Issue 3
Print Edition – Article Let Me Think: Facilitating Deliberation in a Frictionless Economy Carrie L. FloydVolume 43 • Issue 3
Print Edition – Article Partners in Claim: Litigation Funding as Quasi-Partnerships Yifat Naftali Ben Zion & Omer PelledVolume 43 • Issue 3
Print Edition – Article Tort Law at the Frontier of Artificial Intelligence Ketan RamakrishnanVolume 43 • Issue 3
Bulletin Healthcare Law in the First Year After Loper Bright Abbe R. Gluck,† Elle Rothermich†† & Liam Bendicksen†††May 23, 2026
Bulletin Lost-Premium Damages in M&A: Delaware’s New Legal Landscape Jonathan Chan† & Martin Petrin††February 28, 2025
Bulletin Belaboring the Algorithm: Artificial Intelligence and Labor Unions Bradford J. Kelley†June 15, 2024
Notice & Comment Statute by Statute: The Future of ESG After Loper Bright Robert T.F. DownesAugust 12, 2026
Notice & Comment Beyond Psychedelics—What Executive Order 14401 Signals for Drug Regulation and Innovation Patti ZettlerAugust 11, 2026
Notice & Comment Super Placebo Psychedelics: How Might FDA Evaluate Blinding Failure? Julia S. Etkin, Dr. Christopher T. RobertsonAugust 11, 2026
Notice & Comment Justifying Autonomy Interference via Psychedelic Regulation Holly Fernandez Lynch, Dr. Lewis A. GrossmanAugust 10, 2026
Notice & Comment Ad Law Reading Room: “Faithful Agencies,” by Feinstein, Freeman, & Jacobs Daniel DeaconAugust 10, 2026
